Arkansas Supreme Court Takes Different View of Risperdal Fraud Case

Late last year, the federal Department of Justice settled a long-running dispute with drug maker Johnson & Johnson over allegations of the off-label marketing of the anti-psychotic drug Risperdal. As is often the case, Johnson & Johnson also faced several state False Claims Act and Deceptive Trade Practices Act allegations, […]

Pharmaceutical Sales Whistleblower Sheds Light on Off-Label Marketing Scheme

It is unlawful for a pharmaceutical company to market a drug for purposes beyond those that have been approved by the Food and Drug Administration. When a company decides to sell a new drug to American consumers, the FDA ensures the drug is rigorously tested to reveal any deadly or […]